BAGSVAERD, Denmark, Oct. 27 /PRNewswire-FirstCall/ -- Novo Nordisk A/S today announced its financial statement for the period January 1, 2006 to September 30, 2006.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO ) * Reported sales increased by 16% in the first nine months of 2006 - Sales of insulin analogs increased by 52% - Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by 13% - Sales of Norditropin(R) (somatropin [rDNA origin] injection) increased by 21% - Sales in North America increased by 29% - Sales in International Operations increased by 22% * Gross profit increased by 20% reflecting a continued improvement in the production economy, thereby expanding the gross margin by 2.5 percentage points to 75.2%. * Operating profit increased by 14% to USD 1,168 million. * Net profit increased by 1% to USD 788 million, and earnings per share (diluted) increased by 3% to USD 2.43. * The expectation for growth in full-year sales and operating profit is unchanged. Hence, reported sales are still expected to grow by 13-15%, reported operating profit is expected to grow by around 13% while the underlying operating profit growth rate is expected to be around 15%. * In October, the US Food and Drug Administration (FDA) approved the use of NovoSeven(R) for the treatment of acquired hemophilia, a rare but serious bleeding disorder.
Lars Rebien Sorensen, president and CEO, said “Despite increasing competitive pressure, Novo Nordisk’s sales of strategic products continue to perform well. This provides us with a good basis for continuing to deliver attractive growth rates in 2007 and beyond.”
* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 6.00175.
The complete Novo Nordisk earnings announcement can be found at http://www.novonordisk.com.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,750 employees in 79 countries, and markets its products in 179 countries. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk photodesk@prnewswire.comNovo Nordisk A/S
CONTACT: Media: Susan Jackson, +1-609-919-7776, or Investors: MadsVeggerby Lausten, +1-609-919-7937, both of Novo Nordisk
Web site: http://www.novonordisk-us.com//
